Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2026 | Choosing between abiraterone & darolutamide in prostate cancer

Tamim Niazi • 26 Oct 2026
ESMO 2026
Genitourinary Cancer Prostate Cancer Abiraterone Darolutamide
DASL-HiCaP STAMPEDE

Tamim Niazi, McGill University, Montreal, Canada, highlights the regulatory pathway and clinical evidence for androgen receptor inhibitors in prostate cancer treatment, comparing outcomes from the STAMPEDE (NCT00268476) and DASL-HiCaP trial (ANZUP1801; NCT04136353). While STAMPEDE showed negative primary results overall, a subset of patients with pelvic lymph node disease or prior pelvic radiation therapy benefited from additional radiation therapy. The choice between darolutamide and abiraterone hinges on tolerability and toxicity profiles, but the DASL-HiCaP patient population differed from STAMPEDE eligibility criteria. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Tamim Niazi

Sequencing hormone therapy in high-risk localized prostate cancer
0:56
Sequencing hormone therapy in high-risk localized prostate cancer
Tamim Niazi • 26 Oct 2026
DASL-HiCaP: darolutamide with ADT and RT in very high-risk localized prostate cancer
3:22
DASL-HiCaP: darolutamide with ADT and RT in very high-risk localized prostate cancer
Tamim Niazi • 26 Oct 2026
Highlights of ASTRO 2022
0:50
Highlights of ASTRO 2022
Tamim Niazi • 7 Nov 2022
Impact of clinical implementation of hypofractionated radiotherapy on patient quality of life
1:15
Impact of clinical implementation of hypofractionated radiotherapy on patient quality of life
Tamim Niazi • 7 Nov 2022

Related Videos

KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
2:21
KEYNOTE-866: perioperative pembrolizumab with chemotherapy in MIBC
Jens Bedke • 26 Oct 2026
Sequencing hormone therapy in high-risk localized prostate cancer
0:56
Sequencing hormone therapy in high-risk localized prostate cancer
Tamim Niazi • 26 Oct 2026
DASL-HiCaP: darolutamide with ADT and RT in very high-risk localized prostate cancer
3:22
DASL-HiCaP: darolutamide with ADT and RT in very high-risk localized prostate cancer
Tamim Niazi • 26 Oct 2026
VOLGA: perioperative durvalumab and neoadjuvant enfortumab vedotin in MIBC
2:04
VOLGA: perioperative durvalumab and neoadjuvant enfortumab vedotin in MIBC
Thomas Powles • 24 Oct 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals